The direct and indirect effects of COVID‐19 pandemic in a real‐life hematological setting

dc.contributor.authorCondom, Maria
dc.contributor.authorMussetti, Alberto
dc.contributor.authorMaluquer, Clara
dc.contributor.authorParody, Rocío
dc.contributor.authorGonzález Barca, Eva
dc.contributor.authorArnan, Montserrat
dc.contributor.authorAlbasanz Puig, Adaia
dc.contributor.authorPomares, Helena
dc.contributor.authorSalas, Maria Queralt
dc.contributor.authorCarro, Itziar
dc.contributor.authorPeña, Marta
dc.contributor.authorClapes, Victòria
dc.contributor.authorBaca Cano, Cristina
dc.contributor.authorOliveira Ramos, Ana Carla
dc.contributor.authorSanz Linares, Gabriela
dc.contributor.authorMoreno González, Gabriel
dc.contributor.authorMercadal, Santiago
dc.contributor.authorBoqué Genovard, Concepción
dc.contributor.authorGudiol González, Carlota
dc.contributor.authorDomingo Domènech, Eva
dc.contributor.authorSureda, Anna
dc.date.accessioned2021-04-07T07:59:40Z
dc.date.available2021-04-07T07:59:40Z
dc.date.issued2021-03-03
dc.date.updated2021-03-25T07:52:51Z
dc.description.abstractBackground: Clinical outcomes of novel coronavirus 2019 disease (COVID-19) in onco-hematological patients are unknown. When compared to non-immunocompromised patients, onco-hematological patients seem to have higher mortality rates. Aims: We describe the characteristics and outcomes of a consecutive cohort of 24 onco-hematological patients with COVID-19 during the first month of the pandemic. We also describe variations in healthcare resource utilization within our hematology department. Methods and results: Data from patients between the first month of the pandemic were retrospectively collected. Clinical and logistic data were also collected and compared with the average values from the prior 3 months of activity. Prevalence of COVID-19 in our hematological population was 0.4%. Baseline characteristics were as follows: male sex: 83%, lymphoid diseases: 46%, median age: 69 (22-82) years. Median follow-up in survivors was 14 (9-28) days and inpatient mortality rate was 46%. Average time to moderate/severe respiratory insufficiency and death were 3 (1-10) and 10 (3-18) days, respectively. Only 1 out of every 12 patients who developed moderate to severe respiratory insufficiency recovered. Upon univariate analysis, the following factors were associated with higher mortality: age ≥ 70 years (P = .01) and D-dimer ≥900 mcg/L (P = .04). With respect to indirect effects during the COVID-19 pandemic, and when compared with the prior 3 months of activity, inpatient mortality (excluding patients with COVID-19 included in the study) increased by 56%. This was associated with a more frequent use of vasoactive drugs (+300%) and advanced respiratory support (+133%) in the hematology ward. In the outpatient setting, there was a reduction in initial visits (-55%) and chemotherapy sessions (-19%). A significant increase in phone visits was reported (+581%). Conclusion: COVID-19 pandemic is associated with elevated mortality in hematological patients. Negative indirect effects are also evident within this setting.
dc.format.extent10 p.
dc.format.mimetypeapplication/pdf
dc.identifier.pmid33656801
dc.identifier.urihttps://hdl.handle.net/2445/176037
dc.language.isoeng
dc.publisherWiley Periodicals LLC.
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1002/cnr2.1358
dc.relation.ispartofCancer Reports, 2021
dc.relation.urihttps://doi.org/10.1002/cnr2.1358
dc.rightscc by (c) Condom et al., 2021
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceArticles publicats en revistes (Ciències Clíniques)
dc.subject.classificationCOVID-19
dc.subject.classificationOncologia
dc.subject.classificationMalalties hematològiques
dc.subject.otherCOVID-19
dc.subject.otherOncology
dc.subject.otherHematologic diseases
dc.titleThe direct and indirect effects of COVID‐19 pandemic in a real‐life hematological setting
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
cnr2.1358.pdf
Mida:
1.38 MB
Format:
Adobe Portable Document Format